评估PI-RADS v2在非学术机构环境中的诊断表现
回顾性分析170例在单一非学术中心接受前列腺多参数MRI及MR/US融合活检的男性,共282个PI-RADS病灶;PI-RADS v2评分是临床显著前列腺癌的显著预测因子(每增加1分,OR 4.2,95%CI 2.2-8.3),联合PSA密度后AUC由0.69升至0.76。
要点
- PI-RADS v2每增加1分,临床显著前列腺癌的OR为4.2(95%CI 2.2-8.3,P<0.001)。
- PI-RADS v2单独AUC 0.69(95%CI 0.63-0.76),联合PSA密度后AUC 0.76(95%CI 0.69-0.82)。
- PI-RADS 4或5分病灶中,PSAD≥0.15者临床显著前列腺癌发生率约为PSAD<0.15者的2倍(P=0.005)。
核心结论
- PI-RADS v2在非学术机构环境中是临床显著前列腺癌的强预测因子,联合PSA密度可进一步增强其预测能力。
研究设计与样本
- 回顾性分析,纳入2014年11月至2016年3月在单一非学术中心接受前列腺多参数MRI及后续MR/US融合活检的170例男性,共282个PI-RADS病灶;MRI采用3-Tesla扫描仪和表面体线圈,以PI-RADS v2评分,对选定病例行MR/US融合活检;采用混合效应逻辑回归和ROC曲线分析PI-RADS v2单独及联合PSA密度预测临床显著前列腺癌。
诊断标准与关键数值
- PI-RADS v2评分是临床显著前列腺癌的显著预测因子(P<0.001),每增加1分,临床显著前列腺癌的OR为4.2(95%CI 2.2-8.3)。
- PI-RADS v2预测临床显著前列腺癌的AUC为0.69(95%CI 0.63-0.76)。
- PI-RADS v2联合PSA密度预测临床显著前列腺癌的AUC为0.76(95%CI 0.69-0.82),显著高于PI-RADS v2单独(P<0.001)。
- 检测到PI-RADS 4或5分病灶时,PSAD≥0.15组临床显著前列腺癌发生率约为PSAD<0.15组的2倍(P=0.005)。
临床应用与阅片要点
- 在非学术机构环境中,PI-RADS v2评分可用于预测临床显著前列腺癌,联合PSA密度可提高预测效能。
- PI-RADS 4或5分病灶中,PSAD≥0.15提示临床显著前列腺癌风险更高(约为PSAD<0.15者的2倍,P=0.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the utility of PI-RADS v2 to diagnose clinically significant prostate cancer (CS-PCa) with magnetic resonance ultrasound (MR/US) fusion-guided prostate biopsies in the non-academic setting.
MATERIALS/METHODS: Retrospective analysis of men whom underwent prostate multiparametric MRI and subsequent MR/US fusion biopsies at a single non-academic center from 11/2014 to 3/2016. Prostate MRIs were performed on a 3-Tesla scanner with a surface body coil. The Prostate Imaging Reporting and Data System (PI-RADS) v2 scoring algorithm was utilized and MR/US fusion biopsies were performed in selected cases. Mixed effect logistic regression analyses and receiver-operating characteristic (ROC) curves were performed on PI-RADS v2 alone and combined with PSA density (PSAD) to predict CS-PCa.
RESULTS: 170 patients underwent prostate MRI with 282 PI-RADS lesions. MR/US fusion diagnosed 71 CS-PCa, 33 Gleason score 3+3, and 168 negative. PI-RADS v2 score is a statistically significant predictor of CS-PCa (P < 0.001). For each one-point increase in the overall PI-RADS v2 score, the odds of having CS-PCa increases by 4.2 (95% CI 2.2-8.3). The area under the ROC curve for PI-RADS v2 is 0.69 (95% CI 0.63-0.76) and for PI-RADS v2 + PSAD is 0.76 (95% CI 0.69-0.82), statistically higher than PI-RADS v2 alone (P < 0.001). The rate of CS-PCa was about twice higher in men with high PSAD (≥0.15) compared to men with low PSAD (<0.15) when a PI-RADS 4 or 5 lesion was detected (P = 0.005).
CONCLUSION: PI-RADS v2 is a strong predictor of CS-PCa in the non-academic setting and can be further strengthened when utilized with PSA density.
引用
- Jordan EJ, Fiske C, Zagoria RJ, et al. Evaluating the performance of PI-RADS v2 in the non-academic setting. Abdom Radiol (NY). 2017. PMID: 28451763. doi:10.1007/s00261-017-1169-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。